QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: EU Marketing-Authorisation Procedures for Human Medicines

Test your understanding of the concepts covered by Centralised, National, Mutual Recognition and Decentralised Procedures Explained.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which finding most strongly supports classification of a procedure as an MRP rather than a DCP?

The procedure involves more than one Member State An RMS and CMSs are identified A national marketing authorisation and assessment already existed before recognition was sought elsewhere The product information is intended to be harmonised

Question 2 of 10 Which statement correctly describes the relationship between regulatory route and benefit-risk outcome?

A centralised route inherently indicates a more favourable benefit-risk balance A national route inherently indicates a less favourable benefit-risk balance The route determines the assessment architecture but does not itself predict whether the benefit-risk balance is favourable MRP and DCP do not require assessment of benefit-risk balance because they rely on coordination

Question 3 of 10 Why should a regulatory professional distinguish the initial authorisation route from later variations, referrals or safety assessments?

Later procedures are never legally relevant A later procedure may affect the product without changing how its original marketing authorisation was established Only initial applications have procedure numbers A referral automatically converts every national authorisation into a centralised authorisation

Question 4 of 10 Which statement best explains why a medicine can be subject to a Union pharmacovigilance procedure without having been centrally authorised?

Only centrally authorised medicines are subject to EU pharmacovigilance EU pharmacovigilance is networked, and nationally authorised medicines may also enter applicable Union procedures A national authorisation automatically becomes centralised after a safety signal Pharmacovigilance procedures are unrelated to the authorisation route and cannot involve national authorities

Question 5 of 10 A multi-country DCP has completed a coordinated scientific assessment. What is the expected legal nature of the resulting authorisations?

One Union marketing authorisation issued by the European Commission National marketing authorisations in the participating Member States An RMS authorisation valid automatically across the EU A CHMP opinion with no marketing authorisations possible

Question 6 of 10 Why should an unresolved MRP or DCP disagreement not be labelled simply as 'a CHMP referral' without further qualification?

CHMP never participates in any procedure involving nationally authorised medicines Different Union procedures may involve CHMP but address different legal questions and have different procedural histories Only national authorities can issue scientific opinions All referrals have identical legal bases once CHMP is involved

Question 7 of 10 Which combination correctly describes the roles of the RMS and CMSs in an MRP or DCP?

The RMS issues the Union authorisation and CMSs provide only translations The RMS coordinates the assessment, while CMSs participate in reviewing it within the procedure The RMS is an EMA committee and CMSs are European Commission departments The RMS conducts a centralised assessment and CMSs replace the Commission decision

Question 8 of 10 Which document combination would provide the strongest basis for determining whether a product has a centralised marketing authorisation?

The product's commercial name and active substance only A marketing-authorisation decision, relevant EMA or CHMP documentation, and the product's regulatory history A promotional statement that EMA approved the product The country where the applicant's headquarters are located

Question 9 of 10 A product already has a national marketing authorisation in Member State A. The applicant now seeks recognition of that assessment in Member States B and C. Which route is indicated by the starting regulatory state?

Decentralised procedure Centralised procedure Mutual recognition procedure A new national procedure in Member State A only

Question 10 of 10 Which statement best captures the distinction between CMDh and CHMP?

CMDh is responsible for centralised applications, while CHMP coordinates national translations CMDh operates in the coordination framework for nationally authorised medicines and MRP/DCP, while CHMP is an EMA scientific committee for human medicines within its mandate CMDh and CHMP are alternative names for the same committee CHMP is a national authority, while CMDh is the European Commission's legal decision-making body

QPPV.com

Knowledge Assessment: EU Marketing-Authorisation Procedures for Human Medicines

Cookie Settings